Understanding the Impact of the Small Scale Levodopa-Entacapone-Carbidopa-Intestinal-Gel Pump on Everyday Experiences of People Living with Parkinson’s Disease: A Mixed-Methods Evaluation
Objective: This study aims to qualitatively evaluate the impact of switching from the conventional Levodopa-Carbidopa-Intestinal-Gel (LCIG) pump to the smaller sized Levodopa-Entacapone-Carbidopa-Intestinal-Gel (LECIG) pump on…Clinical Features and Trajectories Related to Entacapone Use in Parkinson’s Disease: insights from the French NS Park Cohort
Objective: This study aimed to provide real-life entacapone use in French PD expert centers, focusing on temporal trends, therapeutic positioning, and treatment persistence. Background: Optimizing…Effectiveness of Switching from Levodopa-Carbidopa Intestinal Gel to Levodopa-Carbidopa-Entacapone Intestinal Gel in Patients with Refractory Biphasic and Peak-of-Dose Dyskinesia
Objective: To evaluate the clinical benefit on motor complications of transitioning from levodopa-carbidopa intestinal gel (LCIG) to levodopa-carbidopa-entacapone intestinal gel (LECIG) in a cohort of…Switch from LCIG to LECIG in advanced Parkinson’s Disease: Real World Outcomes from a Single Centre
Objective: To evaluate the clinical outcomes and tolerability of switching from levodopa/carbidopa intestinal gel (LCIG) to levodopa/carbidopa/entacapone intestinal gel (LECIG) in patients with advanced Parkinson’s…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…Three-Year Single-Center Experience with Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in advanced Parkinson’s Disease (APD). Background: LECIG infusion has been available in Romania since 2021.…Split tablet dosing of Levodopa/Carbidopa/Entacapone 100mg/25mg/200mg in treating Chinese patients with early Parkinson’s disease: a single-center, prospective cohort study
Objective: To investigate split tablet dosing of Levodopa/Carbidopa/Entacapone (LCE) 100mg/25mg/200mg in treating Chinese patients with early Parkinson’s disease (PD). Background: LCE is a treatment option…Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage
Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study
Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson’s disease: a two-year experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in the treatment of patients with advanced Parkinson’s Disease (APD). Background: The continuous enteral infusion…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.